Rhinomed May 2017 Investor Update - Delivering End To End Sleep Category Solutions
Disrupting the US$ 32 Billion Global Sleep Apnea Market
Melbourne, May 16, 2017 - (ABN Newswire) - Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) are pleased to provide the Company's latest Investor Update for May 2017.
Highlights include:
GROWING REVENUE FROM IN MARKET PRODUCTS
- Two applications already brought to market- both of which are nasal stents.
- One in four people will have a problem breathing through their nose.
- Turbine and Mute help people to breathe better, sleep better and enjoy a better quality of life.
Turbine:
- Helps athletes to breathe easier during sport and aerobic exercise and overcome nasal obstruction
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US$24.95 delivering strong margins
Mute:
- Helps breathing at night, improves nasal airflow and may alleviate snoring
- Adjustable for each nostril to ensure comfort and fit
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US$24.95 delivering strong margins
MUTE TARGETS ONE OF THE FASTEST GROWING MARKETS IN HEALTH - SLEEP
- Sleep Aids Market estimated to be US$ 7 Billion in 2015
- Forecast to grow to US$ 10 billion by 2020 at a CAGR of 6.4% from 2016 to 2020.
DELIVERING REVENUE GROWTH
Steady growth in units shipped to customers:
- Up 25% in Q3
- Total units shipped FY17 YTD - 116,000
GROWTH DRIVERS
Retail:
- Scale in store numbers in Australia, USA, Canada and UK - Target: 13,000 FY17
- Premium in-store experience and presence - Drive sell-through
- Establish Mute technology as the entry point to the global sleep category
Online:
- Leading provider of content that informs and educates
- Curate an active and vibrant community and conversation
Clinical:
- Become the preferred solution for nasal obstruction by Doctors and Dentists
To view the complete Investor Presentation, please visit: http://abnnewswire.net/lnk/R5239612
About: Rhinomed Ltd
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.
Melbourne, May 16, 2017 - (ABN Newswire) - Rhinomed Ltd (ASX:RNO) (OTCMKTS:RHNMF) are pleased to provide the Company's latest Investor Update for May 2017.
Highlights include:
GROWING REVENUE FROM IN MARKET PRODUCTS
- Two applications already brought to market- both of which are nasal stents.
- One in four people will have a problem breathing through their nose.
- Turbine and Mute help people to breathe better, sleep better and enjoy a better quality of life.
Turbine:
- Helps athletes to breathe easier during sport and aerobic exercise and overcome nasal obstruction
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US$24.95 delivering strong margins
Mute:
- Helps breathing at night, improves nasal airflow and may alleviate snoring
- Adjustable for each nostril to ensure comfort and fit
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US$24.95 delivering strong margins
MUTE TARGETS ONE OF THE FASTEST GROWING MARKETS IN HEALTH - SLEEP
- Sleep Aids Market estimated to be US$ 7 Billion in 2015
- Forecast to grow to US$ 10 billion by 2020 at a CAGR of 6.4% from 2016 to 2020.
DELIVERING REVENUE GROWTH
Steady growth in units shipped to customers:
- Up 25% in Q3
- Total units shipped FY17 YTD - 116,000
GROWTH DRIVERS
Retail:
- Scale in store numbers in Australia, USA, Canada and UK - Target: 13,000 FY17
- Premium in-store experience and presence - Drive sell-through
- Establish Mute technology as the entry point to the global sleep category
Online:
- Leading provider of content that informs and educates
- Curate an active and vibrant community and conversation
Clinical:
- Become the preferred solution for nasal obstruction by Doctors and Dentists
To view the complete Investor Presentation, please visit: http://abnnewswire.net/lnk/R5239612
About: Rhinomed Ltd
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.